Dyadic International, Inc. filed a Form 8-K with the SEC on November 13, 2026, announcing the release of its financial results for the quarter ended September 30, 2026.
Rare Earths Americas, Inc. filed a Form 8-K on November 13, 2026, reporting the voting outcomes from its 2026 Annual Meeting of Stockholders held on November 12, 2026.
Douglas J. Grimm, Interim CEO and Director of Fox Factory Holding Corp, filed a Form 4 on November 13, 2026, disclosing the acquisition of 112,677 restricted stock units on November 10, 2026.
Director Ciaran Murray filed an amended Form 144 notice with the SEC on November 13, 2026, updating the shares outstanding figure for a proposed sale of ICON Public Limited Company common stock on NASDAQ.
Massachusetts Financial Services Company filed an amended ownership disclosure with the SEC on November 13, 2026, reporting its beneficial holdings in TransUnion (NYSE:TRU) common stock as of September 30, 2026.
Donald Smith & Co., Inc. and DSCO Value Fund, L.P. filed a Schedule 13G with the SEC on November 13, 2026, disclosing aggregate beneficial ownership of 2,770,303 shares of PennyMac Financial Services, Inc. common stock, representing 5.3% of the class, as of September 30, …
Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven A.J. Salamon, and Aharon Gil filed Amendment No. 9 to a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership in PolyPid Ltd. as of September 30, 2026.
Donald Smith & Co., Inc. and DSCO Value Fund, L.P. filed a Schedule 13G with the SEC on November 13, 2026, disclosing aggregate beneficial ownership of 14,114,034 shares of Park Hotels & Resorts Inc. common stock, representing 7.0% of the class, as of September …
Credit Agricole S.A. filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 1,468,681,745 shares of Vodafone Group Public Limited Company common stock, representing 6.04% of the class, as of September 30, 2026.
Boston Partners filed an amended Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 8,002,638 shares of Cytek Biosciences, Inc. common stock as of September 30, 2026.